236 related articles for article (PubMed ID: 10548319)
1. Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients.
Paris PL; Kupelian PA; Hall JM; Williams TL; Levin H; Klein EA; Casey G; Witte JS
Cancer Epidemiol Biomarkers Prev; 1999 Oct; 8(10):901-5. PubMed ID: 10548319
[TBL] [Abstract][Full Text] [Related]
2. Impact of a genetic variant in CYP3A4 on risk and clinical presentation of prostate cancer among white and African-American men.
Bangsi D; Zhou J; Sun Y; Patel NP; Darga LL; Heilbrun LK; Powell IJ; Severson RK; Everson RB
Urol Oncol; 2006; 24(1):21-7. PubMed ID: 16414488
[TBL] [Abstract][Full Text] [Related]
3. Characterization of an allelic variant in the nifedipine-specific element of CYP3A4: ethnic distribution and implications for prostate cancer risk. Mutations in brief no. 191. Online.
Walker AH; Jaffe JM; Gunasegaram S; Cummings SA; Huang CS; Chern HD; Olopade OI; Weber BL; Rebbeck TR
Hum Mutat; 1998; 12(4):289. PubMed ID: 10660343
[TBL] [Abstract][Full Text] [Related]
4. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4.
Rebbeck TR; Jaffe JM; Walker AH; Wein AJ; Malkowicz SB
J Natl Cancer Inst; 1998 Aug; 90(16):1225-9. PubMed ID: 9719084
[TBL] [Abstract][Full Text] [Related]
5. CYP3A4-V and prostate cancer in African Americans: causal or confounding association because of population stratification?
Kittles RA; Chen W; Panguluri RK; Ahaghotu C; Jackson A; Adebamowo CA; Griffin R; Williams T; Ukoli F; Adams-Campbell L; Kwagyan J; Isaacs W; Freeman V; Dunston GM
Hum Genet; 2002 Jun; 110(6):553-60. PubMed ID: 12107441
[TBL] [Abstract][Full Text] [Related]
6. Ethnic differences in the frequency of prostate cancer susceptibility alleles at SRD5A2 and CYP3A4.
Zeigler-Johnson CM; Walker AH; Mancke B; Spangler E; Jalloh M; McBride S; Deitz A; Malkowicz SB; Ofori-Adjei D; Gueye SM; Rebbeck TR
Hum Hered; 2002; 54(1):13-21. PubMed ID: 12446983
[TBL] [Abstract][Full Text] [Related]
7. Cyp17 promoter variant associated with prostate cancer aggressiveness in African Americans.
Kittles RA; Panguluri RK; Chen W; Massac A; Ahaghotu C; Jackson A; Ukoli F; Adams-Campbell L; Isaacs W; Dunston GM
Cancer Epidemiol Biomarkers Prev; 2001 Sep; 10(9):943-7. PubMed ID: 11535545
[TBL] [Abstract][Full Text] [Related]
8. CYP3A4: a potential prostate cancer risk factor for high-risk groups.
Zeigler-Johnson C
Clin J Oncol Nurs; 2001; 5(4):153-4. PubMed ID: 12690615
[TBL] [Abstract][Full Text] [Related]
9. CYP3A4 polymorphisms--potential risk factors for breast and prostate cancer: a HuGE review.
Keshava C; McCanlies EC; Weston A
Am J Epidemiol; 2004 Nov; 160(9):825-41. PubMed ID: 15496535
[TBL] [Abstract][Full Text] [Related]
10. CYP3A4 and CYP3A5 genotypes, haplotypes, and risk of prostate cancer.
Plummer SJ; Conti DV; Paris PL; Curran AP; Casey G; Witte JS
Cancer Epidemiol Biomarkers Prev; 2003 Sep; 12(9):928-32. PubMed ID: 14504207
[TBL] [Abstract][Full Text] [Related]
11. Human CYP1B1 Leu432Val gene polymorphism: ethnic distribution in African-Americans, Caucasians and Chinese; oestradiol hydroxylase activity; and distribution in prostate cancer cases and controls.
Tang YM; Green BL; Chen GF; Thompson PA; Lang NP; Shinde A; Lin DX; Tan W; Lyn-Cook BD; Hammons GJ; Kadlubar FF
Pharmacogenetics; 2000 Dec; 10(9):761-6. PubMed ID: 11221602
[TBL] [Abstract][Full Text] [Related]
12. Population distribution and effects on drug metabolism of a genetic variant in the 5' promoter region of CYP3A4.
Ball SE; Scatina J; Kao J; Ferron GM; Fruncillo R; Mayer P; Weinryb I; Guida M; Hopkins PJ; Warner N; Hall J
Clin Pharmacol Ther; 1999 Sep; 66(3):288-94. PubMed ID: 10511065
[TBL] [Abstract][Full Text] [Related]
13. CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5'-promoter region polymorphism.
Wandel C; Witte JS; Hall JM; Stein CM; Wood AJ; Wilkinson GR
Clin Pharmacol Ther; 2000 Jul; 68(1):82-91. PubMed ID: 10945319
[TBL] [Abstract][Full Text] [Related]
14. More about: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4.
Rebbeck TR
J Natl Cancer Inst; 2000 Jan; 92(1):76. PubMed ID: 10620637
[No Abstract] [Full Text] [Related]
15. CYP3A4 promoter variant is associated with prostate cancer risk in men with benign prostate hyperplasia.
Tayeb MT; Clark C; Sharp L; Haites NE; Rooney PH; Murray GI; Payne SN; McLeod HL
Oncol Rep; 2002; 9(3):653-5. PubMed ID: 11956645
[TBL] [Abstract][Full Text] [Related]
16. Association of RNASEL variants with prostate cancer risk in Hispanic Caucasians and African Americans.
Shook SJ; Beuten J; Torkko KC; Johnson-Pais TL; Troyer DA; Thompson IM; Leach RJ
Clin Cancer Res; 2007 Oct; 13(19):5959-64. PubMed ID: 17908993
[TBL] [Abstract][Full Text] [Related]
17. CYP3A4 genetic variant and disease-free survival among white and black men after radical prostatectomy.
Powell IJ; Zhou J; Sun Y; Sakr WA; Patel NP; Heilbrun LK; Everson RB
J Urol; 2004 Nov; 172(5 Pt 1):1848-52. PubMed ID: 15540736
[TBL] [Abstract][Full Text] [Related]
18. Lung cancer risk in relation to the CYP2C9*1/CYP2C9*2 genetic polymorphism among African-Americans and Caucasians in Los Angeles County, California.
London SJ; Daly AK; Leathart JB; Navidi WC; Idle JR
Pharmacogenetics; 1996 Dec; 6(6):527-33. PubMed ID: 9014202
[TBL] [Abstract][Full Text] [Related]
19. CYP3A4 and VDR gene polymorphisms and the risk of prostate cancer in men with benign prostate hyperplasia.
Tayeb MT; Clark C; Haites NE; Sharp L; Murray GI; McLeod HL
Br J Cancer; 2003 Mar; 88(6):928-32. PubMed ID: 12644831
[TBL] [Abstract][Full Text] [Related]
20. Genetic contribution to variable human CYP3A-mediated metabolism.
Lamba JK; Lin YS; Schuetz EG; Thummel KE
Adv Drug Deliv Rev; 2002 Nov; 54(10):1271-94. PubMed ID: 12406645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
